Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

Grifols United Kingdom England Italy Spain

Grifols sCD38 is the industry's first-ever soluble recombinant protein designed to overcome the interference that the cancer therapy daratumumab has on critical blood-transfusion testsThe solution prevents daratumumab, which targets the CD38 protein on cancer cells, from binding to this specific protein on red blood cells and interfering in pre-transfusion compatibility testingGrifols sCD38 has received the CE mark and is another example of the company's commitment to ensure the safety of the world's blood supplyView original content:https://www.prnewswire.co.uk/news-releases/grifols-launches-new-solution-to-facilitate-pre-transfusion-compatibility-testing-in-multiple-myeloma-patients-301989753.html